Studying tumor tissue to predict drug resistance in stomach cancer
Part of Cancer, Digestive system clinical trials.
This study looks at tissue samples from stomach or gastroesophageal junction cancer to understand how the tumor interacts with its surroundings, which may help predict if the cancer will resist treatment. All participants will receive standard chemotherapy (FLOT) plus durvalumab before and after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma (a common type of cancer) of the stomach or the area where the stomach meets the esophagus.
- Your cancer is operable (can be surgically removed) and is locally advanced — it has not spread to distant parts of the body.
- You are scheduled to receive chemotherapy (FLOT) combined with durvalumab (an immunotherapy drug) before and after surgery.
- You are 18 years or older.
- You do not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This trial tests a new combination of chemotherapy and an immunotherapy drug (durvalumab) given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it shrinks the tumor and improves outcomes.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.